Undergraduate Degree

  • Harvard University , Cambridge , MA

Medical School

  • Yale University School of Medicine , New Haven , CT


  • Boston Combined Residency Program (BCRP) , Boston , MA


  • Boston Combined Residency Program (BCRP) , Boston , MA


Pediatric Rheumatology
  • Boston Children's Hosital , Boston , MA


Dr. Hazen is a graduate of Harvard University and the Yale School of Medicine and completed her pediatric residency and rheumatology fellowship training at the Boston Children's Hospital where she has remained on faculty as a pediatric Division of General Pediatrics and rheumatology attending. Dr. Hazen's clinical practice is devoted to the care of complex patients, including hospitalized children and children with immune-mediated illness. She is the co-founder and co-director of a multidisciplinary clinic, the MAID clinic, devoted the the care of and improving the understanding of children with monogenic immune dysregulatory syndromes. She is the director of quality improvement for the Rheumatology Program and is the site PI for a national pediatric rheumatology quality improvement collaborative, PR-COIN. She is interested in the intersection of pediatric Division of General Pediatrics, rheumatology, and quality improvement, and she has co-developed clinical practice guidelines for the care of patients with rheumatic disease (eg HLH/MAS, KD, FUO) for use by hospitalists and sub-specialists.


  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Pediatric Rheumatology


Publications powered by Harvard Catalyst Profiles

  1. Th1 polarization defines the synovial fluid T cell compartment in oligoarticular juvenile idiopathic arthritis. JCI Insight. 2021 Sep 22; 6(18). View abstract
  2. A multidisciplinary assessment of pain in juvenile idiopathic arthritis. Semin Arthritis Rheum. 2021 08; 51(4):700-711. View abstract
  3. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View abstract
  4. Vasculitis as a Major Morbidity Factor in Patients With Partial RAG Deficiency. Front Immunol. 2020; 11:574738. View abstract
  5. Providing Inpatient Medical Care to Children With Autism Spectrum Disorder. Hosp Pediatr. 2020 10; 10(10):918-924. View abstract
  6. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020 07; 72(7):1059-1063. View abstract
  7. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020 03 26; 5(6). View abstract
  8. The immunologic features of patients with early-onset and polyautoimmunity. Clin Immunol. 2020 02; 211:108326. View abstract
  9. Defining a new immune deficiency syndrome: MAN2B2-CDG. J Allergy Clin Immunol. 2020 03; 145(3):1008-1011. View abstract
  10. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019 12; 78(12):1722-1731. View abstract
  11. Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. J Allergy Clin Immunol Pract. 2019 Jul - Aug; 7(6):1970-1985.e4. View abstract
  12. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View abstract
  13. Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. Ann Rheum Dis. 2017 04; 76(4):765-772. View abstract
  14. Next-Generation Sequencing Reveals Restriction and Clonotypic Expansion of Treg Cells in Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2016 07; 68(7):1758-68. View abstract
  15. Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. J Exp Med. 2015 Jun 01; 212(6):939-51. View abstract
  16. Trainee and program director perceptions of quality improvement and patient safety education: preparing for the next accreditation system. Clin Pediatr (Phila). 2014 Nov; 53(13):1248-54. View abstract
  17. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol. 2013 Oct; 132(4):969-71.e1-2. View abstract
  18. A taste of periodic fever syndromes. Pediatr Emerg Care. 2013 Jul; 29(7):842-8; quiz 849-51. View abstract
  19. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013 May; 65(5):745-52. View abstract
  20. Multiple juvenile idiopathic arthritis subtypes demonstrate proinflammatory IgG glycosylation. Arthritis Rheum. 2012 Sep; 64(9):3025-33. View abstract
  21. Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Res Ther. 2012 Mar 05; 14(2):R43. View abstract
  22. Regulation of human neutrophil Fc? receptor IIa by C5a receptor promotes inflammatory arthritis in mice. Arthritis Rheum. 2011 Feb; 63(2):467-78. View abstract
  23. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010 Aug; 62(8):2239-48. View abstract
  24. Mutations of the HLH-associated gene UNC13D (MUNC13-4) in a patient with systemic juvenile idiopathic arthritis. Arthritis and Rheumatism. 2008; 58:567-570. View abstract
  25. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2008 Feb; 58(2):567-70. View abstract
  26. Mutations of the HLH-associated gene UNC13D (MUNC13-4) in a patient with systemic juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting. 2007. View abstract
  27. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. Journal of Clinical Investigation. 2005; 115:1177-1187. View abstract
  28. Escape from Immune Surveillance Does Not Result in Tolerance to Tumor-Associated Antigens. Journal of Immunotherapy. 2004; 27:329. View abstract
  29. Characterization of the Immune Responses to the Tumor-Associated HY-Antigen. 2002. View abstract
  30. Progressive Tumor Growth in a Model Tumor Antigen System Does Not Induce Immunologic Tolerance but Appears to Induce Weak Immunity Toward Tumor Antigens. American Society of Hematology Meeting. 2001. View abstract